Literature DB >> 18201852

An improved and fully validated LC-MS/MS method for the simultaneous quantification of simvastatin and simvastatin acid in human plasma.

Constantinos Apostolou1, Constantinos Kousoulos, Yannis Dotsikas, Georgios-Stefanos Soumelas, Filomila Kolocouri, Afroditi Ziaka, Yannis L Loukas.   

Abstract

A fully automated high-throughput liquid chromatography/tandem mass spectrometry (LC-MS/MS) method was developed for the simultaneous quantification of simvastatin (SV) and simvastatin acid (SVA) in human plasma. Plasma samples were treated by acetonitrile (ACN) addition for protein precipitation (PP) and subsequent two-step liquid-liquid extraction (LLE) in 96-deepwell plates, using methyl t-butyl ether (MTBE) as the organic solvent. ACN addition step was proven to enhance method sensitivity, as well as producing cleaner samples for injection. Lovastatin (LV) and lovastatin acid (LVA) were used as internal standards (IS) for SV and SVA quantification respectively. A relatively small plasma volume (300 microL) was employed and all procedure liquid transfer steps were performed automatically, by the use of robotic liquid handling workstations. Both electrospray (ESI) and atmospheric pressure chemical ionization (APCI) sources were applied and compared for LC-MS/MS sample analysis, with ESI proven to be more sensitive for the specific analytes. Polarity switch (from negative to positive ionization mode) was performed during the same analytical run, so as for the simultaneous SV and SVA determination to be possible. The method had a short sample preparation time, as well as a chromatographic run time of just 1.9 min, the shortest so far reported for SV determination. It was validated and fulfilled all preset criteria for sensitivity, specificity, linearity (0.100-40.0 ng/mL), inter- and intra-accuracy and precision for both molecules. The proposed method was applied to the rapid and reliable simultaneous determination of SV and SVA in a bioequivalence study, after per os administration of a SV tablet (80 mg).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18201852     DOI: 10.1016/j.jpba.2007.12.001

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  6 in total

1.  Gender differences in pharmacokinetics of a combination tablet of niacin extended-release/simvastatin in healthy Chinese volunteers.

Authors:  Xiao-lin Wang; Man Liu; Man Yang; Ya-nan Zhang; Dan Zhang; Li-na Zhang; Jing Han; Hui-chen Liu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-12-18       Impact factor: 2.441

2.  No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.

Authors:  Jenni E Keskitalo; Kaisa J Kurkinen; Mikko Neuvonen; Janne T Backman; Pertti J Neuvonen; Mikko Niemi
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

Review 3.  Innovations in asthma therapy: is there a role for inhaled statins?

Authors:  Amir A Zeki; Mona Elbadawi-Sidhu
Journal:  Expert Rev Respir Med       Date:  2018-05-03       Impact factor: 3.772

4.  A Simple Protein Precipitation-based Simultaneous Quantification of Lovastatin and Its Active Metabolite Lovastatin Acid in Human Plasma by Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry using Polarity Switching.

Authors:  Ju Wujian; Peng Kuan-Wei; Yang Sihyung; Sun Huijing; Sampson Mario; Wang Michael Zhuo
Journal:  J Chromatogr Sep Tech       Date:  2015-05

5.  Synthesis, characterization and quantification of simvastatin metabolites and impurities.

Authors:  Manish S Bhatia; Swapnil D Jadhav; Neela M Bhatia; Prafulla B Choudhari; Kundan B Ingale
Journal:  Sci Pharm       Date:  2011-07-25

6.  Validated LC-MS/MS method for simultaneous determination of SIM and its acid form in human plasma and cell lysate: Pharmacokinetic application.

Authors:  Tamer A Ahmed; Jamie Horn; John Hayslip; Markos Leggas
Journal:  J Pharm Anal       Date:  2012-08-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.